National Drug Schedules: Addition of mometasone nasal spray as a "drug not reviewed"
August 18, 2015
Mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older was removed from the Health Canada Prescription Drug List on August 12, 2015. In accordance with the NAPRA Policy for Drugs Not Reviewed, this drug was placed on Schedule I of the National Drug Schedules (NDS) and identified accordingly effective August 18, 2015. The status of this drug in the NDS can only change in the future if a submission is presented to NAPRA for a review by the National Drug Scheduling Advisory Committee (NDSAC).